Danaher Corporation $DHR Shares Newly Purchased by Eagle Strategies LLC

Eagle Strategies LLC acquired a new position in Danaher Corporation (NYSE:DHR) during the 3rd quarter, HoldingsChannel.com reports. The firm acquired 9,461 shares of the conglomerate’s stock, valued at approximately $2,096,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Gunderson Capital Management LLC bought a new stake in Danaher during the 3rd quarter valued at $765,000. EP Wealth Advisors LLC bought a new stake in Danaher in the 2nd quarter worth $3,807,000. Puzo Michael J bought a new stake in Danaher in the 2nd quarter worth $8,624,000. Madison Asset Management LLC purchased a new position in shares of Danaher in the second quarter valued at about $85,451,000. Finally, First Nebraska Trust Co purchased a new position in shares of Danaher in the second quarter valued at about $14,106,000. Institutional investors own 79.05% of the company’s stock.

Analysts Set New Price Targets

DHR has been the subject of several recent analyst reports. Guggenheim upped their price objective on shares of Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Royal Bank Of Canada raised their target price on Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research note on Monday, October 5th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $240.00 target price on shares of Danaher in a research note on Wednesday, July 22nd. TD Cowen boosted their price target on Danaher from $236.00 to $255.00 and gave the company a “buy” rating in a report on Tuesday. Finally, UBS Group initiated coverage on Danaher in a research report on Wednesday, September 9th. They set a “buy” rating and a $250.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $235.41.

Danaher Stock Performance

Shares of DHR stock opened at $228.87 on Friday. The firm has a market capitalization of $160.89 billion, a price-to-earnings ratio of 40.65, a PEG ratio of 2.91 and a beta of 0.76. The stock has a fifty day moving average of $214.04 and a 200 day moving average of $195.97. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. During the same period in the previous year, the firm earned $0.77 EPS. The company’s quarterly revenue was up 5.5% compared to the same quarter last year. As a group, research analysts expect that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.40 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. Danaher’s payout ratio is presently 28.42%.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.